Logotipo del repositorio
Logotipo del repositorio
 

Consenso latinoamericano de síndrome hemolítico urémico atípico

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2
dc.contributor.authorNieto-Ríos, John F.
dc.contributor.authorBello Márquez, Diana Carolina
dc.contributor.authorMORALES-BUENROSTRO, LUIS
dc.contributor.authorMusalem, Pilar
dc.contributor.authorVaisbich, Maria Helena
dc.contributor.authorFortunato, Rita M.
dc.contributor.authorGómez-Navarro, Benjamín
dc.contributor.authorJiménez-Acosta, Darío
dc.contributor.authorMaldonado , Rafael Alberto
dc.contributor.authorTrimarchi, Hernán
dc.contributor.authorRico-Fontalvo, Jorge
dc.date.accessioned2025-10-30T15:27:51Z
dc.date.available2025-10-30T15:27:51Z
dc.date.issued2025
dc.description.abstractEl síndrome hemolítico urémico atípico primario es una microangiopatía trombótica relacionada con una alteración en la regulación de la vía alterna del complemento, caracterizada por daño endotelial difuso, hemólisis microangiopática y compromiso orgánico multisistémico, ocasionando una alta morbimortalidad. Su diagnóstico diferencial incluye la púrpura trombocitopénica trombótica, el síndrome hemolítico urémico relacionado con la toxina Shiga y las microangiopatías trombóticas secundarias. En su evaluación son fundamentales la medición de la actividad de la enzima ADAMTS-13, la determinación de la toxina Shiga en materia fecal o con pruebas moleculares que identifiquen las bacterias productoras de esta toxina, el estudio de enfermedades sistémicas que causan microangiopatías trombóticas y la realización de pruebas genéticas de la regulación de la vía alterna del complemento. El tratamiento de elección es la inhibición de la fracción C5 del complemento con fármacos como el eculizumab y el ravulizumab. El pronóstico depende de un diagnóstico temprano y de un tratamiento oportuno. En Latinoamérica, este síndrome ha sido escasamente estudiado y hay pocos consensos que unifiquen los criterios de evaluación y manejo.spa
dc.description.abstractPrimary atypical hemolytic uremic syndrome is a thrombotic microangiopathy associated with altered regulation of the alternate complement pathway. It is characterized by diffuse endothelial damage, microangiopathic hemolysis, and multisystem organ involvement, causing high morbidity and mortality. Its differential diagnosis includes thrombotic thrombocytopenic purpura, Shiga toxin-associated hemolytic uremic syndrome, and secondary thrombotic microangiopathies. Its evaluation includes measuring ADAMTS-13 enzyme activity, determining Shiga toxin in fecal matter, or using molecular tests to identify the bacteria that produce this toxin. Its evaluation also includes the study of systemic diseases that cause thrombotic microangiopathies and performing genetic testing for regulation of the alternate complement pathway. The treatment of choice is inhibition of the C5 fraction of complement with drugs such as eculizumab and ravulizumab. The prognosis depends on early diagnosis and timely treatment. In Latin America, this syndrome has been poorly studied, and there is little consensus that unifies evaluation and management criteria.eng
dc.format.mimetypepdf
dc.identifier.doi10.24875/NEFRO.M25000070
dc.identifier.issn24449032
dc.identifier.urihttps://hdl.handle.net/20.500.12442/17066
dc.identifier.urlhttps://www.nefrologialatinoamericana.com/portadas/nefro_25_22_supl-2.pdf
dc.language.isospa
dc.publisherSociedad Latinoamericana de Nefrología e Hipertensiónspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationaleng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceNefrología Latinoamericanaspa
dc.subjectMicroangiopatías trombóticasspa
dc.subjectSíndrome hemolítico urémico atípicospa
dc.subjectIntercambio plasmáticospa
dc.subjectEculizumabspa
dc.subjectRavulizumabspa
dc.subject.keywordsThrombotic microangiopathieseng
dc.subject.keywordsAtypical Hemolytic Uremic Syndromeeng
dc.subject.keywordsPlasma exchangeeng
dc.titleConsenso latinoamericano de síndrome hemolítico urémico atípicospa
dc.title.translatedLatin American consensus on atypical hemolytic uremic syndromeeng
dc.type.driverinfo:eu-repo/semantics/article
dc.type.spaArtículo científico
dcterms.referencesRamos Bolaños E, Martínez del Valle A, Nieto Estrada VH. Consenso Internacional de Diagnóstico y Manejo de Microangiopatías Trombóticas Primarias 2023-2024. Disponible en: https://acho.com.co/wp-content/ uploads/2024/05/Consenso-Internacional-de-MAT-primarias-2024.pdf.spa
dcterms.referencesAbou‐Ismail MY, Kapoor S, Citla Sridhar D, Nayak L, Ahuja S. Thrombotic microangiopathies: an illustrated review. Res Pract Thromb Haemost. 2022;6(3):e12708.eng
dcterms.referencesGeorge JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654-66.eng
dcterms.referencesBrocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13(2):300-17.eng
dcterms.referencesCampistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, et al. Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso. Nefrología. 2015;35(5):421-47.spa
dcterms.referencesManrique-Caballero CL, Peerapornratana S, Formeck C, Del Río-Pertuz G, Gómez Danies H, Kellum JA. Typical and atypical hemolytic uremic syndrome in the critically ill. Crit Care Clin. 2020;36(2):333-56.eng
dcterms.referencesWada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. 2018;16(1):14.eng
dcterms.referencesWerion A, Storms P, Zizi Y, Beguin C, Bernards J, Cambier JF, et al. Epidemiology, outcomes, and complement gene variants in secondary thrombotic microangiopathies. Clin J Am Soc Nephrol. 2023;18(7):881-91.eng
dcterms.referencesNester CM, Feldman DL, Burwick R, Cataland S, Chaturvedi S, Cook HT, et al. An expert discussion on the atypical hemolytic uremic syndrome nomenclature — identifying a road map to precision: a report of a National Kidney Foundation Working Group. Kidney Int. 2024;106(3):326-36.eng
dcterms.referencesSepúlveda Palamara RA, Modelli De Andrade LG, Fortunato RM, Gómez B, Nieto-Ríos JF. Clinical presentation and management of atypical hemolytic uremic syndrome in Latin America: a narrative review of the literature. Expert Rev Hematol. 2024;17(7):361-74.eng
dcterms.referencesGoodship THJ, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539-51.eng
dcterms.referencesCórdoba J, Contreras K, Larrarte C, Espitaleta Z, González L, Ibarra M, et al. Síndrome hemolítico urémico atípico, revisión de la literatura y documento de consenso. Enfoque diagnóstico y tratamiento. Rev Colomb Nefrol. 2015;2(1):19-40.spa
dcterms.referencesPraga M, Rodríguez De Córdoba S. Secondary atypical hemolytic uremic syndromes in the era of complement blockade. Kidney Int. 2019;95(6):1298-300.eng
dcterms.referencesLe Clech A, Simon-Tillaux N, Provôt F, Delmas Y, Vieira-Martins P, Limou S, et al. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney Int. 2019;95(6):1443-52.eng
dcterms.referencesNieto-Ríos JF, Zuluaga-Quintero M, Higuita LMS, Rincón CIG, Galvez- Cárdenas KM, Ocampo-Kohn C, et al. Hemolytic uremic syndrome due to gemcitabine in a young woman with cholangiocarcinoma. J Bras Nefrol. 2016;38(2):255-9.eng
dcterms.referencesNieto-Ríos JF, García-Prada CA, Aristizabal-Alzate A, Zuluaga-Valencia G, Cadavid-Aljure D, Serna-Higuita LM, et al. Nephrotic syndrome as a manifestation of thrombotic microangiopathy due to long-term use of sunitinib. Nefrol Engl Ed. 2022;42(6):722-6.eng
dcterms.referencesMatar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation. 2014;98(11):1205-12.eng
dcterms.referencesMubarak M, Raza A, Rashid R, Sapna F, Shakeel S. Thrombotic microangiopathy after kidney transplantation: expanding etiologic and pathogenetic spectra. World J Transplant. 2024;14(1):90277.eng
dcterms.referencesLoirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1): 15-39.eng
dcterms.referencesDixon BP, Gruppo RA. Atypical hemolytic uremic syndrome. Pediatr Clin N Am. 2018;65(3):509-25.eng
dcterms.referencesYerigeri K, Kadatane S, Mongan K, Boyer O, Burke LL, Sethi SK, et al. Atypical hemolytic-uremic syndrome: genetic basis, clinical manifestations, and a multidisciplinary approach to management. J Multidiscip Healthc. 2023;16:2233-49.eng
dcterms.referencesNoris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676-87eng
dcterms.referencesTseng MH, Lin SH, Tsai JD, Wu MS, Tsai IJ, Chen YC, et al. Atypical hemolytic uremic syndrome: consensus of diagnosis and treatment in Taiwan. J Formos Med Assoc. 2023;122(5):366-75.eng
dcterms.referencesRaina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, et al. Atypical hemolytic‐uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4-21.eng
dcterms.referencesLaurence J, Haller H, Mannuci P, Nangaku M, Praga M, Rodríguez De Córdoba S. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;(Suppl 11):2-15.eng
dcterms.referencesFakhouri F, Schwotzer N, Frémeaux-Bacchi V. How I diagnose and treat atypical hemolytic uremic syndrome. Blood. 2023;141(9):984-95.eng
dcterms.referencesNoris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-59.eng
dcterms.referencesSellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8):2392-400.eng
dcterms.referencesFakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol. 2017;12(1):50-9.eng
dcterms.referencesFremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Duley M, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide french series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-62.eng
dcterms.referencesDelvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, et al. Thrombomodulin mutations in atypical hemolytic–uremic syndrome. N Engl J Med. 2009;361(4):345-57.eng
dcterms.referencesYoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of atypical hemolytic uremic syndrome. J Atheroscler Thromb. 2019;26(2):99-110.eng
dcterms.referencesFakhouri F, Sadallah S, Frémeaux-Bacchi V. Malignant hypertension and thrombotic microangiopathy: complement as a usual suspect. Nephrol Dial Transplant. 2021;36(7):1157-9.eng
dcterms.referencesHalimi JM, Al-Dakkak I, Anokhina K, Ardissino G, Licht C, Lim WH, et al. Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the Global aHUS registry. J Nephrol. 2022;36(3):817-28.eng
dcterms.referencesBello-Marquez DC, Nieto-Rios JF, Serna-Higuita LM, Gonzalez-Vergara AJ. Nephrotic syndrome associated with primary atypical hemolytic uremic syndrome. Braz J Nephrol. 2021;43(3):440-4.eng
dcterms.referencesMalina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F. Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics. 2013;131(1):e331-5.eng
dcterms.referencesNieto-Ríos JF, Serna-Higuita LM, Calle-Botero E, Ocampo-Kohn C, Aristizabal- Alzate A, Zuluaga-Quintero M, et al. Síndrome hemolítico urémico atípico en un paciente joven con compromiso renal, neurológico, ocular y cardiovascular. Nefrologia. 2016;36(1):82-5.spa
dcterms.referencesZimmerhackl LB, Scheiring J, Prüfer F, Taylor CM, Loirat C. Renal transplantation in HUS patients with disorders of complement regulation. Pediatr Nephrol. 2007;22(1):10-6.eng
dcterms.referencesLe Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13(3):663-75.eng
dcterms.referencesBeck BB, Van Spronsen F, Diepstra A, Berger RMF, Kömhoff M. Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. Pediatr Nephrol. 2017;32(5):733-41.eng
dcterms.referencesPalma LMP, Sridharan M, Sethi S. Complement in secondary thrombotic microangiopathy. Kidney Int Rep. 2021;6(1):11-23.eng
dcterms.referencesKohli R, Geneen LJ, Brunskill SJ, Doree C, Estcourt L, Chee SEJ, et al. Assessing efficacy and safety of replacement fluids in therapeutic plasma exchange: a systematic scoping review of outcome measures used. J Clin Apher. 2022;37(5):438-48.eng
dcterms.referencesLemaire A, Parquet N, Galicier L, Boutboul D, Bertinchamp R, Malphettes M, et al. Plasma exchange in the intensive care unit: technical aspects and complications. J Clin Apheresis. 2017;32(6):405-12.eng
dcterms.referencesHou R, Tian W, Qiao R, Zhang J. Efficacy of albumin and compounded plasma for plasma exchange in acquired thrombotic thrombocytopenic purpura. J Clin Apheresis. 2020;35(3):154-62.eng
dcterms.referencesKeenswijk W, Raes A, De Clerck M, Vande Walle J. Is plasma exchange efficacious in Shiga toxin‐associated hemolytic uremic syndrome? A narrative review of current evidence. Ther Apher Dial. 2019;23(2):118-25.eng
dcterms.referencesCervantes CE, Bloch EM, Sperati CJ. Therapeutic plasma exchange: core curriculum 2023. Am J Kidney Dis. 2023;81(4):475-92.eng
dcterms.referencesPan Z, Zhang Z, Yang J, Hao W. The efficacy and safety of plasma exchange in the treatment of thrombotic thrombocytopenic purpura. J Healthc Eng. 2022;3519937.eng
dcterms.referencesPadmanabhan A, Connelly‐Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice — evidence‐based approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apheresis. 2019;34(3):171-354.eng
dcterms.referencesContreras E, De La Rubia J, Del Río-Garma J, Díaz-Ricart M, García-Gala JM, Lozano M. Guía diagnóstica y terapéutica de las microangiopatías trombóticas del Grupo Español de Aféresis. Med Clin. 2015;144(7):331.e1-13.spa
dcterms.referencesWinters JL. Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP). Hematology. 2017;2017(1):632-8.eng
dcterms.referencesO’Brien KL, Price TH, Howell C, Delaney M. The use of 50% albumin/ plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura. J Clin Apheresis. 2013;28(6):416-21.eng
dcterms.referencesMariotte E, Veyradier A. Thrombotic thrombocytopenic purpura: from diagnosis to therapy. Curr Opin Crit Care. 2015;21(6):593-601.eng
dcterms.referencesLoirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6(1):60.eng
dcterms.referencesClaes KJ, Massart A, Collard L, Weekers L, Goffin E, Pochet JM, et al. Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clin Belg. 2018;73(1):80-9.eng
dcterms.referencesZuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11):643-57.eng
dcterms.referencesFakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis. 2014;63(1):40-8.eng
dcterms.referencesHeinen S, Pluthero FG, Van Eimeren VF, Quaggin SE, Licht C. Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Mol Immunol. 2013;54(1):84-8.eng
dcterms.referencesDavin JC, Strain L, Goodship THJ. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol. 2008;23(9):1517-21.eng
dcterms.referencesLapeyraque AL, Wagner E, Phan V, Clermont MJ, Merouani A, Frémeaux- Bacchi V, et al. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol. 2008;23(8):1363-6.eng
dcterms.referencesChatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault De Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic–uremic syndrome. Am J Transplant. 2009;9(11):2644-5.eng
dcterms.referencesLhotta K, Janecke AR, Scheiring J, Petzlberger B, Giner T, Fally V, et al. A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol. 2009;4(8):1356-62.eng
dcterms.referencesDragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, et al. Clinical features of anti-factor H autoantibody–associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010;21(12):2180-7.eng
dcterms.referencesStrobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, et al. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2010;25(1):136-44.eng
dcterms.referencesKwon T, Dragon-Durey MA, Macher MA, Baudouin V, Maisin A, Peuchmaur M, et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant. 2008;23(6):2088-90.eng
dcterms.referencesLionet A, Provot F, Glowacki F, Fremeaux-Bacchi V, Hazzan M. A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab. NDT Plus. 2009;2(6):458-60.eng
dcterms.referencesBoyer O, Balzamo E, Charbit M, Biebuyck-Gougé N, Salomon R, Dragon- Durey MA, et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti–complement factor H autoantibodies. Am J Kidney Dis. 2010;55(5):923-7.eng
dcterms.referencesMartin IW, Katus MC, Martin CB, Szczepiorkowski ZM, Gorham JD, Dunbar NM. Rapid ADAMTS 13 availability impacts treatment for microangiopathic hemolytic anemia and thrombocytopenia. J Clin Apheresis. 2016;31(5):419-22.eng
dcterms.referencesAriceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24(4):687-96.eng
dcterms.referencesTaylor CM, Machin S, Wigmore SJ, Goodship THJ; Working Party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol. 2010;148(1):37-47.eng
dcterms.referencesSyed YY. Ravulizumab: a review in atypical haemolytic uraemic syndrome. Drugs. 2021;81:587-94.eng
dcterms.referencesRondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2020;97(6):1287-96.eng
dcterms.referencesAriceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2021;100(1):225-37.eng
dcterms.referencesZuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337-54.eng
dcterms.referencesZuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, et al. Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2019;30(12):2449-63.eng
dcterms.referencesBamhraz AA, Rahim KA, Faqeehi HY, Alanazi A. Improved renal recovery with eculizumab therapy among children with high prevalence of mutation- associated atypical hemolytic uremic syndrome: a retrospective cohort study. Kidney Blood Press Res. 2020;45(6):939-54eng
dcterms.referencesde Souza R, Correa BHM, Melo PHM, Pousa PA, C de Mendonça TS, Castelar Rodriguez LG, et al. The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review. Pediatr Nephrol. 2023;38:61-75.eng
dcterms.referencesFakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68(1):84-93.eng
dcterms.referencesArdissino G, Cresseri D, Mancuso MC, Capone V, Porcaro L, Amico V, et al. Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition. J Nephrol. 2024;37(4):1017-26.eng
dcterms.referencesBendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157-64.eng
dcterms.referencesSchaefer F, Al-Dakkak I, Anokhina K, Cohen D, Greenbaum LA, Ariceta G. Global aHUS registry analysis of patients switching to ravulizumab from eculizumab. Kidney Int Rep. 2024;9(9):2648-56.eng
dcterms.referencesAlZabali S, AlBatati S, Rahim K, Faqeehi H, Osman A, Bamhraz A, et al. A Multicenter study evaluating the discontinuation of eculizumab therapy in children with atypical hemolytic uremic syndrome. Children. 2022;9:1734-45.eng
dcterms.referencesAriceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS) — a question to be addressed in a scientific way. Pediatr Nephrol. 2019;34(5):943-9.eng
dcterms.referencesÁvila A, Cao M, Espinosa M, Manrique J, Morales E. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Front Med. 2023;10:1264310.eng
dcterms.referencesRondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab safety: five-year experience from the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney Int Rep. 2019;4(11):1568-76.eng
dcterms.referencesDiep J, Potter D, Mai J, Hsu D. Atypical haemolytic uremic syndrome with refractory multiorgan involvement and heterozygous CFHR1/CFHR3 gene deletion. BMC Nephrol. 2023;24(127):1-7.eng
dcterms.referencesRiedl M, Hofer J, Giner T, Rosales A, Häffner K, Simonetti GD, et al. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. J Immunol Methods. 2016;435:60-7.eng
dcterms.referencesTer Avest M, Steenbreker H, Bouwmeester RN, Duinevel C, Wijnsma K, van den Heuvel L, et al. Proteinuria and exposure to eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2023;18(6):759-66.eng
dcterms.referencesWada H, Teranishi H, Shimono A, Kato N, Maruyama S, Matsumoto M. Application of a scoring system in Japanese patients diagnosed with atypical hemolytic uremic syndrome to assess the relationship between the score and clinical responses to eculizumab. Thromb J. 2023;21(43): 1-12.eng
dcterms.referencesMenne J, Delmas Y, Fakhouri F, Licht C, Lommelé A, Minetti EE, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019;20(1):125.eng
dcterms.referencesKato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, et al. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic– uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol. 2019;23(1):65-75.eng
dcterms.referencesAl Riyami D, Mohammed S, Al Salmi I, Metry A, Al Kalbani N, Almurshadi F, et al. Epidemiology, management, and outcome of atypical hemolytic uremic syndrome in an Omani cohort. Oman Med J. 2023;38(6):e569.eng
dcterms.referencesNoris M, Bresin E, Mele C. Genetic atypical hemolytic-uremic syndrome. GeneReviews. 2007;16:1-26.eng
dcterms.referencesCheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, et al. Clinical practice guidelines for the management of atypical hemolytic uremic syndrome in Korea. J Korean Med Sci. 2016;31(10):1516.eng
dcterms.referencesSchönfelder K, Kühne L, Schulte-Kemna L, Kaufeld J, Rohn H, Kribben A, et al. Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS — real-world data. BMC Nephrol. 2024;25(1):202.eng
dcterms.referencesTang ZC, Hui H, Shi C, Chen X. New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses. Ren Fail. 2023;45(1):2231264.eng
dcterms.referencesDixon BP, Kavanagh D, Aris ADM, Adams B, Kang HG, Wang E, et al. Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-year efficacy and safety outcomes in 2 phase 3 trials. Kidney Med. 2024;6(8):100855.eng
dcterms.referencesSchoettler M, Lehmann L, Li A, Ma C, Duncan C. Thrombotic microangiopathy following pediatric autologous hematopoietic cell transplantation: a report of significant end-organ dysfunction in eculizumab-treated survivors. Biol Blood Marrow Transplant. 2019;25(5):e163-8.eng
dcterms.referencesCavero T, Rabasco C, López A, Román E, Ávila A, Sevillano A, et al. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017;32(3):466-74.eng
dcterms.referencesLewis LA, Ram S. Meningococcal disease and the complement system. Virulence. 2014;5(1):98-126.eng
dcterms.referencesRoss S, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of Neisserial and other infections in an immune deficiency. Medicine (Baltimore). 1984;63(5):243-72.eng
dcterms.referencesCrew PE, McNamara L, Waldron PE, McCulley L, Jones SC, Bersoff-Matcha SJ. Unusual Neisseria species as a cause of infection in patients taking eculizumab. J Infect. 2019;78(2):113-8.eng
dcterms.referencesO’Leary ST, Kimberlin DW. Update from the Advisory Committee on Immunization Practices. J Pediatr Infect Dis Soc. 2017;6(4):311-6.eng
dcterms.referencesAlashkar F, Vance C, Herich-Terhürne D, Preising N, Dührsen U, Röth A. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab. Ann Hematol. 2017;96(4):589-96.eng
dcterms.referencesLangereis JD, Van Den Broek B, Franssen S, Joosten I, Blijlevens NMA, De Jonge MI, et al. Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients. Blood Adv. 2020;4(15):3615-20.eng
dcterms.referencesMcNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734-7.eng
dcterms.referencesSocié G, Caby‐Tosi M, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297-310.eng
dcterms.referencesDessaix K, Bontoux C, Aubert O, Grünenwald A, Sberro Soussan R, Zuber J, et al. De novo thrombotic microangiopathy after kidney transplantation in adults: interplay between complement genetics and multiple endothelial injury. Am J Transplant. 2024;24(7):1205-17.eng
dcterms.referencesÁvila A, Gavela E, Sancho A. Thrombotic microangiopathy after kidney transplantation: an underdiagnosed and potentially reversible entity. Front Med. 2021;8:642864.eng
dcterms.referencesLeon J, LeStang M, Sberro‐Soussan R, Servais A, Anglicheau D, Frémeaux‐ Bacchi V, et al. Complement‐driven hemolytic uremic syndrome. Am J Hematol. 2023;98:s44-56.eng
dcterms.referencesVon Tokarski F, Fillon A, Maisons V, Thoreau B, Bayer G, Gatault P, et al. Thrombotic microangiopathies after kidney transplantation in modern era: nosology based on chronology. BMC Nephrol. 2023;24(1):278.eng
dcterms.referencesNoris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant. 2010;10(7):1517-23.eng
dcterms.referencesReynolds JC, Lawrence YA, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis. 2003;42(5):1058-68.eng
dcterms.referencesFortin MC, Raymond MA, Madore F, Fugère JA, Pâquet M, St-Louis G, et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin–sirolimus combination. Am J Transplant. 2004;4(6):946-52.eng
dcterms.referencesDa Silva RL. Viral-associated thrombotic microangiopathies. Hematol Oncol Stem Cell Ther. 2011;4(2):51-9.eng
dcterms.referencesPetr V, Hruba P, Kollar M, Krejci K, Safranek R, Stepankova S, et al. Rejection- associated phenotype of de novo thrombotic microangiopathy represents a risk for premature graft loss. Transplant Direct. 2021;7(11):e779.eng
dcterms.referencesReyes‐Vargas E, Pavlov IY, Martins TB, Schwartz JJ, Hill HR, Delgado JC. Binding of anti‐HLA class I antibody to endothelial cells produce an inflammatory cytokine secretory pattern. J Clin Lab Anal. 2009;23(3):157-60.eng
dcterms.referencesAgustian PA, Bockmeyer CL, Modde F, Wittig J, Heinemann FM, Brundiers S, et al. Glomerular mRNA expression of prothrombotic and antithrombotic factors in renal transplants with thrombotic microangiopathy. Transplantation. 2013;95(10):1242-8.eng
dcterms.referencesGarg N, Rennke HG, Pavlakis M, Zandi-Nejad K. De novo thrombotic microangiopathy after kidney transplantation. Transplant Rev. 2018;32(1):58-68.eng
dcterms.referencesLe Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant. 2008;8(8):1694-701.eng
dcterms.referencesKarthikeyan V, Parasuraman R, Shah V, Vera E, Venkat KK. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant. 2003;3(10):1289-94.eng
dcterms.referencesDhakal P, Giri S, Pathak R, Bhatt VR. Eculizumab in transplant-associated thrombotic microangiopathy. Clin Appl Thromb. 2017;23(2):175-80.eng
dcterms.referencesAbbas F, Kossi ME, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: current insights in de novo and recurrent disease. World J Transplant. 2018;8(5):122-41.eng
dcterms.referencesMeehan SM, Kremer J, Ali FN, Curley J, Marino S, Chang A, et al. Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies. Clin J Am Soc Nephrol. 2011;6(2):395-403.eng
dcterms.referencesSatoskar AA, Pelletier R, Adams P, Nadasdy GM, Brodsky S, Pesavento T, et al. De novo thrombotic microangiopathy in renal allograft biopsies — role of antibody-mediated rejection. Am J Transplant. 2010;10(8):1804-11eng
dcterms.referencesGlover EK, Smith-Jackson K, Brocklebank V, Wilson V, Walsh PR, Montgomery EK, et al. Assessing the impact of prophylactic eculizumab on renal graft survival in atypical hemolytic uremic syndrome. Transplantation. 2023;107(4):994-1003.eng
dcterms.referencesGonzalez Suarez ML, Thongprayoon C, Mao MA, Leeaphorn N, Bathini T, Cheungpasitporn W. Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with eculizumab: a systematic review and meta-analysis. J Clin Med. 2019;8(7):919.eng
dcterms.referencesNieto-Ríos JF, Zuluaga-Quintero M, Bello-Márquez DC, Serna-Higuita LM, Aristizábal-Alzate A, Ocampo-Kohn C, et al. Trasplante renal exitoso con protocolo de eculizumab, timoglobulina, tacrolimus, micofenolato y esteroides en paciente con síndrome hemolítico urémico atípico sin mutación identificada. NefroPlus. 2018;10(2):63-8.eng
dcterms.referencesNieto-Ríos JF, Zuluaga-Quintero M, Bello-Márquez DC, Aristizabal-Alzate A, Ocampo-Kohn C, Serna-Higuita LM, et al. Trasplante renal exitoso con protocolo de eculizumab, timoglobulina y belatacept en paciente altamente sensibilizada con síndrome hemolítico urémico atípico por mutación del factor H. Nefrologia. 2018;38(4):433-7.spa
dcterms.referencesMusalem P, Pedreros-Rosales C, Müller-Ortiz H, Gutiérrez-Navarro C, Carpio JD. Complement-mediated thrombotic microangiopathy after kidney transplant: should treatment with C5 inhibitor be lifelong? Nephron. 2024;148(11-12):780-4.eng
dcterms.referencesGómez Navarro B. 50 preguntas claves en microangiopatías trombóticas. México: Permanyer México; 2021. 33 p.spa
dcterms.referencesHolmes C, Simpson K, Okada H, Okada N, Wainwright, Purcel D, et al. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol. 1992;22(6):1579-85.eng
dcterms.referencesFakhouri F. Pregnancy-related thrombotic microangiopathies: clues from complement biology. Transfus Apher Sci. 2016;54(2):199-202.eng
dcterms.referencesFakhouri F, Roumenina L, Provot F, Sallée M, Caillard S, Couzi L, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859-67.eng
dcterms.referencesEgbor M, Johnson A, Harris F, Makanjoula D, Shehata H. Pregnancy-associated atypical haemolytic uraemic syndrome in the postpartum period: a case report and review of the literature. Obstet Med. 2011;4(2):83-5.eng
dcterms.referencesBruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol. 2017;12(8):1237-47.eng
dcterms.referencesAsif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol. 2017;30(3):347-62.eng
dcterms.referencesGupta M, Govindappagari S, Burwick RM. Pregnancy-associated atypical hemolytic uremic syndrome: a systematic review. Obstet Gynecol. 2020;135(1):46-58.eng
dcterms.referencesGeorge JN. The association of pregnancy with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Curr Opin Hematol. 2003;10(5):339-44.eng
dcterms.referencesJava A, Lyon S, Urra M, Teodosiu C, Burwick R. Complement-mediated disorders of pregnancy. En: Meena P, Chaudhury AR, Sahay M, Gopalakrishnan N, editores. Pregnancy & Kidney Disease. New Delhi, India: Jaypee Brothers; 2024. p. 56-67.eng
dcterms.referencesXiao J, Feng Y, Li X, Li W, Fan L, Liu J, et al. Expression of ADAMTS13 in normal and abnormal placentae and its potential role in angiogenesis and placenta development. Arterioscler Thromb Vasc Biol. 2017;37(9):1748-56.eng
dcterms.referencesRimaitis K, Grauslyte L, Zavackiene A, Baliuliene V, Nadisauskiene R, Macas A. Diagnosis of HELLP syndrome: a 10-year survey in a perinatology centre. Int J Environ Res Public Health. 2019;16(1):109.eng
dcterms.referencesFakhouri F, Scully M, Ardissino G, Al-Dakkak I, Miller B, Rondeau E. Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. J Nephrol. 2021;34(5):1581-90.eng
dcterms.referencesSilver RM. Catastrophic antiphospholipid syndrome and pregnancy. Semin Perinatol. 2018;42(1):26-32.eng
dcterms.referencesHanouna G, Morel N, Le Thi Huong D, Josselin L, Vauthier-Brouzes D, Saadoun D, et al. Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. Rheumatology. 2013;52(9):1635-41.eng
dcterms.referencesUrra M, Lyons S, Teodosiu CG, Burwick R, Java A. Thrombotic microangiopathy in pregnancy: current understanding and management strategies. Kidney Int Rep. 2024;9(8):2353-71.eng
dcterms.referencesKeiser SD, Boyd KW, Rehberg JF, Elkins S, Owens MY, Sunesara I, et al. A high LDH to AST ratio helps to differentiate pregnancy-associated thrombotic thrombocytopenic purpura (TTP) from HELLP syndrome. J Matern Fetal Neonatal Med. 2012;25(7):1059-63.eng
dcterms.referencesChinchilla AK, Madhusudan V, Taveras García B, Jim B. Complement- mediated disorders in pregnancy. Adv Chronic Kidney Dis. 2020; 27(2):155-64.eng
dcterms.referencesLegendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic– uremic syndrome. N Engl J Med. 2013;368(23):2169-81.eng
dcterms.referencesRock G, Shumak K, Buskard N, Blanchette V, Kelton J, Nair R, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325(6): 393-7.eng
dcterms.referencesBrocklebank V, Walsh PR, Smith-Jackson K, Hallam TM, Marchbank KJ, Wilson V, et al. Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study. Blood. 2023; 142(16):1371-86.eng
dcterms.referencesElabd H, Elkholi M, Steinberg L, Acharya A. Eculizumab, a novel potential treatment for acute kidney injury associated with preeclampsia/HELLP syndrome. BMJ Case Rep. 2019;12(9):e228709.eng
dcterms.referencesBurwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/ HELLP syndrome. Placenta. 2013;34(2):201-3.eng
dcterms.referencesFakhouri F, Scully M, Provôt F, Blasco M, Coppo P, Noris M, et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood. 2020;136(19): 2103-17.eng
dcterms.referencesGäckler A, Schönermarck U, Dobronravov V, La Manna G, Denker A, Liu P, et al. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. BMC Nephrol. 2021;22(1):5.eng
dcterms.referencesKelly RJ, Höchsmann B, Szer J, Kulasekararaj A, De Guibert S, Röth A, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032-9.eng
dcterms.referencesPalma LMP, Vaisbich-Guimarães MH, Sridharan M, Tran CL, Sethi S. Thrombotic microangiopathy in children. Pediatr Nephrol. 2022;37(9): 1967-80.eng
dcterms.referencesAndreoli SP, Trachtman H, Acheson DWK, Siegler RL, Obrig TG. Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Proceedings of the American Society of Pediatric Nephrology Educational Symposium, May 2000, Boston, Massachusetts, USA. Pediatr Nephrol. 2002;17(4):293-8.eng
dcterms.referencesWater AM, Kerecuk L, Luk D, Haq MR, Fitzpatrick MM, Gilbert RD, et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr. 2007;151(2):140-4.eng
dcterms.referencesScobell RR, Kaplan BS, Copelovitch L. New insights into the pathogenesis of Streptococcus pneumoniae–associated hemolytic uremic syndrome. Pediatr Nephrol. 2020;35(9):1585-91.eng
dcterms.referencesCabrera G, Fortenberry J, Warshaw B, Chambliss C, Butler J, Cooperstone B. Hemolytic uremic syndrome associated with invasive Streptococcus pneumoniae infection. Pediatrics. 1998;101:699-703.eng
dcterms.referencesKremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primer. 2017;3(1):17020.eng
dcterms.referencesVaisbich MH, Braga A, Gabrielle M, Bueno C, Piazzon F, Kok F. Thrombotic microangiopathy caused by methionine synthase deficiency: diagnosis and treatment pitfalls. Pediatr Nephrol. 2017;32(6):1089-92.eng
dcterms.referencesCornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF, et al. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis. 2014;63(1):119-23.eng
dcterms.referencesBiran V, Fau S, Jamal T, Veinberg F, Renolleau S, Gold F, et al. Perinatal asphyxia may present with features of neonatal atypical hemolytic uremic syndrome. Pediatr Nephrol. 2007;22(12):2129-32.eng
dcterms.referencesVaisbich MH, Andrade LG, Barbosa M. Recommendations for diagnosis and treatment of atypical hemolytic uremic syndrome (aHUS) — an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN). Braz Soc Nephrol. 2025;47(2):e20240087.eng
dcterms.referencesFallahpour M, Hafizi A, Fouladgar A, Rajabian B. Neonatal atypical hemolytic uremic syndrome may cause prenatal asphyxia. Arch Iran Med. 2012;15:729-30.eng
dcterms.referencesBoyer O, Niaudet P. Hemolytic-uremic syndrome in children. Clin North Am. 2022;69:1181-97.eng
dcterms.referencesVaisbich MH, De Andrade LGM, De Menezes Neves PDM, Palma LMP, De Castro MCR, Silva CAB, et al. Baseline characteristics and evolution of Brazilian patients with atypical hemolytic uremic syndrome: first report of the Brazilian aHUS Registry. Clin Kidney J. 2022;15(8):1601-11eng
dcterms.referencesSchaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94(2):408-18.eng
dcterms.referencesToh CH, Hoots WK; Scientific and Standardization Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis. The scoring system of the Scientific and Standardization Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost. 2007;5(3):604–6.eng
dcterms.referencesScully M. How to evaluate and treat the spectrum of TMA syndromes in pregnancy. Hematology Am Soc Hematol Educ Program. 2021;2021(1):545–51.eng
dcterms.referencesFakhouri F. Pregnancy-related thrombotic microangiopathies: clues from complement biology. Transfus Apher Sci. 2016 Apr;54(2):199–202. doi:10.1016/j.transci.2016.04.009.eng
oaire.versioninfo:eu-repo/semantics/publishedVersion

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
PDF.pdf
Tamaño:
2.72 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca